Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.

Détails

ID Serval
serval:BIB_8F707FC7C0D0
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.
Périodique
The International journal on drug policy
Auteur(s)
Grebely J., Conway B., Cunningham E.B., Fraser C., Moriggia A., Gane E., Stedman C., Cooper C., Castro E., Schmid P., Petoumenos K., Hajarizadeh B., Marks P., Erratt A., Dalgard O., Lacombe K., Feld J.J., Bruneau J., Daulouede J.P., Powis J., Bruggmann P., Matthews G.V., Kronborg I., Shaw D., Dunlop A., Hellard M., Applegate T.L., Crawford S., Dore G.J.
Collaborateur(s)
D3FEAT Study Group
ISSN
1873-4758 (Electronic)
ISSN-L
0955-3959
Statut éditorial
Publié
Date de publication
12/2018
Peer-reviewed
Oui
Volume
62
Pages
94-103
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Direct-acting antiviral therapy for hepatitis C virus (HCV) infection is safe and effective, but there are little data among people who have recently injected drugs. This study evaluated the efficacy, and safety of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin for chronic HCV genotype (G) 1 among people with recent injecting drug use and/or receiving OST.
D3FEAT is an international open-label study that recruited treatment-naïve participants with recent injecting drug use (previous 6 months) and/or receiving OST with chronic HCV G1 infection between June 2016 and February 2017 in seven countries. Participants received paritaprevir/ritonavir, ombitasvir, dasabuvir with (G1a) or without ribavirin (G1b) administered twice daily in a one-week electronic blister pack (records timing of each dose) for 12 weeks. The primary endpoint was undetectable HCV RNA 12 weeks post-treatment (SVR12).
Among 87 participants (median age 48 years), 23% were female, 8% had cirrhosis, and 90% had G1a. Overall, 71% were receiving OST, 61% injected in the previous six months, 45% injected in the previous month, and 15% injected > daily. Treatment completion was 97% (84 of 87). There were no virological breakthroughs, but three discontinuations (loss to follow-up, n = 1; non-adherence, n = 1; incarceration, n = 1). SVR was 91% (79 of 87, 95% CI, 83%-96%). Five participants who completed treatment did not have SVR (loss to follow-up, n = 1; death, n = 1; virologic relapse, n = 3). Drug use prior to and during treatment did not impact SVR12. Treatment-related adverse events were observed in 46 (53%) patients (six grade 3, no grade 4). Five (6%) patients had at least one serious adverse event (two possibly/probably related to therapy; nausea and myoclonus). Two cases of reinfection were observed.
Paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for 12 weeks is effective among people with HCV genotype 1 with recent injecting drug use and/or receiving OST.
Mots-clé
DAA, Drug use, Hepatitis C, Injecting drug users, PWID, Treatment
Pubmed
Web of science
Création de la notice
09/11/2018 13:09
Dernière modification de la notice
20/08/2019 15:53
Données d'usage